247 related articles for article (PubMed ID: 25277195)
1. MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.
Codo P; Weller M; Meister G; Szabo E; Steinle A; Wolter M; Reifenberger G; Roth P
Oncotarget; 2014 Sep; 5(17):7651-62. PubMed ID: 25277195
[TBL] [Abstract][Full Text] [Related]
2. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
3. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D.
Heinemann A; Zhao F; Pechlivanis S; Eberle J; Steinle A; Diederichs S; Schadendorf D; Paschen A
Cancer Res; 2012 Jan; 72(2):460-71. PubMed ID: 22102694
[TBL] [Abstract][Full Text] [Related]
6. Natural killer group 2D receptor and its ligands in cancer immune escape.
Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
[TBL] [Abstract][Full Text] [Related]
7. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.
Hilpert J; Grosse-Hovest L; Grünebach F; Buechele C; Nuebling T; Raum T; Steinle A; Salih HR
J Immunol; 2012 Aug; 189(3):1360-71. PubMed ID: 22730533
[TBL] [Abstract][Full Text] [Related]
9. NKG2D ligands in glioma stem-like cells: expression in situ and in vitro.
Flüh C; Chitadze G; Adamski V; Hattermann K; Synowitz M; Kabelitz D; Held-Feindt J
Histochem Cell Biol; 2018 Mar; 149(3):219-233. PubMed ID: 29356965
[TBL] [Abstract][Full Text] [Related]
10. Attribution of NKG2DL to the inhibition of early stage allogeneic tumors in mice.
Hua L; Fang M; Dong B; Guo S; Cui C; Liu J; Yao Y; Xiao Y; Li X; Ren Y; Meng X; Hao X; Zhao P; Song Y; Wang L; Yu Y
Oncotarget; 2016 Dec; 7(50):82369-82383. PubMed ID: 27448968
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.
Crane CA; Han SJ; Barry JJ; Ahn BJ; Lanier LL; Parsa AT
Neuro Oncol; 2010 Jan; 12(1):7-13. PubMed ID: 20150362
[TBL] [Abstract][Full Text] [Related]
12. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression.
Mittelbronn M; Platten M; Zeiner P; Dombrowski Y; Frank B; Zachskorn C; Harter PN; Weller M; Wischhusen J
Acta Neuropathol; 2011 Sep; 122(3):353-65. PubMed ID: 21773885
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor.
Lee HK; Bier A; Cazacu S; Finniss S; Xiang C; Twito H; Poisson LM; Mikkelsen T; Slavin S; Jacoby E; Yalon M; Toren A; Rempel SA; Brodie C
PLoS One; 2013; 8(2):e54652. PubMed ID: 23390502
[TBL] [Abstract][Full Text] [Related]
14. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
Weiss T; Schneider H; Silginer M; Steinle A; Pruschy M; Polić B; Weller M; Roth P
Clin Cancer Res; 2018 Feb; 24(4):882-895. PubMed ID: 29162646
[No Abstract] [Full Text] [Related]
15. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.
Peng L; Ming Y; Zhang L; Zhou J; Xiang W; Zeng S; He H; Chen L
FASEB J; 2020 Apr; 34(4):5128-5143. PubMed ID: 32067282
[TBL] [Abstract][Full Text] [Related]
16. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo.
Wischhusen J; Friese MA; Mittelbronn M; Meyermann R; Weller M
J Neuropathol Exp Neurol; 2005 Jun; 64(6):523-8. PubMed ID: 15977644
[TBL] [Abstract][Full Text] [Related]
17. GDF-15 contributes to proliferation and immune escape of malignant gliomas.
Roth P; Junker M; Tritschler I; Mittelbronn M; Dombrowski Y; Breit SN; Tabatabai G; Wick W; Weller M; Wischhusen J
Clin Cancer Res; 2010 Aug; 16(15):3851-9. PubMed ID: 20534737
[TBL] [Abstract][Full Text] [Related]
18. MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation.
Delic S; Lottmann N; Stelzl A; Liesenberg F; Wolter M; Götze S; Zapatka M; Shiio Y; Sabel MC; Felsberg J; Reifenberger G; Riemenschneider MJ
Neuro Oncol; 2014 Jan; 16(2):179-90. PubMed ID: 24305703
[TBL] [Abstract][Full Text] [Related]
19. MiRNA expression profiling in human gliomas: upregulated miR-363 increases cell survival and proliferation.
Conti A; Romeo SG; Cama A; La Torre D; Barresi V; Pezzino G; Tomasello C; Cardali S; Angileri FF; Polito F; Ferlazzo G; Di Giorgio R; Germanò A; Aguennouz M
Tumour Biol; 2016 Oct; 37(10):14035-14048. PubMed ID: 27495233
[TBL] [Abstract][Full Text] [Related]
20. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.
Friese MA; Wischhusen J; Wick W; Weiler M; Eisele G; Steinle A; Weller M
Cancer Res; 2004 Oct; 64(20):7596-603. PubMed ID: 15492287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
